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Epileptic disorders are a well-known adverse effect of b-
lactams. However, the epileptogenicity of drugs in this class varies
widely.1,2 This paper reports a case of myoclonus induced by
meropenem, a carbapenem with low proconvulsive activity.2
2. Case study
A 61-year-old woman was seen at the intensive care unit
because of myoclonic status. Her medical history included arterial
hypertension, dyslipidemia and diabetes. In the previous year she
had been hospitalized because of dilated cardiomyopathy (ejection
fraction 21%) and non-sustained ventricular tachycardia. At that
time she was managed with an implantable cardiac deﬁbrillator.
On this admission she complained of precordial pain and had heart
failure with a cold and dry proﬁle, for which she was given
vasoactive drugs and an intra-aortic balloon. Her coronary
angiography was unremarkable, but a lower limb echo-Doppler
revealed a high-ﬂow arteriovenous ﬁstula between the right
superﬁcial femoral artery and vein. The ﬁstula was not managed
surgically because of the patient’s clinical status. In the following
days her dyspnea worsened, requiring non-invasive ventilation,
and her central catheter became colonized. She developed oliguria,
vomiting, hypoglycemia, syncope and cardiac arrest, which was
successfully managed with cardiopulmonary resuscitation (CPR). A
urinary infection ensued 5 days later and as her renal function had
decreased, intravenous meropenem 1000 mg/day was started
(dosing for CrCl of 10–25 mL/min: 500–1500 mg/day). Soon after* Corresponding author at: Rua General Carneiro 1103/102, Centro, Curitiba, PR,
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myoclonic jerks involving her shoulder girdle, arms, neck and face.
The myoclonic jerks were attributed to renal impairment
(urea = 159 mg/dL) and she underwent two hemodialysis sessions
without any change in myoclonic status, at which point a
neurologist was called. She was disoriented in time and space
but able to follow commands. No focal neurological deﬁcits were
found. Her prolonged electroencephalography (EEG) recording
revealed spike-wave and polyspike-wave activity (Fig. 1) that was
suppressed after 1 mg of intravenous diazepam and eliminated
after a second dose, suggesting myoclonus of cortical origin.
As diagnostic exploration continued, other toxic and metabolic
conditions were sought. The patient’s blood glucose levels never
exceeded 180 mg/dL, she never went into a hyperosmolar state and
she was afebrile and hemodynamically stable. The main laboratory
ﬁndings are shown in Table 1. On the days when myoclonus
occurred she was also taking norepinephrine, dobutamine,
furosemide, amiodarone, heparin, citalopram and mirtazapine.
None of the doses had changed signiﬁcantly from the previous
days. The only drug started immediately before the onset of
myoclonus was meropenem, which was then attributed as the
cause of the condition.
After clearance of diazepam, myoclonus recurred and abated
only when meropenem was withdrawn and substituted with
cefepime. No other prescription changes were needed. There was
no recurrence of myoclonus after meropenem had been with-
drawn, but unfortunately the patient died a month later because of
clinical complications associated with her heart condition.
Discussion
Myoclonus is a clinical sign deﬁned as a sudden, brief,
involuntary movement caused by muscle contractions or inhibi-
tions.3 EEG recordings provide valuable information for classiﬁca-
tion of myoclonus as generalized spikes or spike-waves are
strongly suggestive of a cortical or cortical-subcortical origin while
subcortical-supraspinal, spinal or peripheral myoclonus are not
associated with any epileptiform discharges or other consistent
electroencephalographic abnormalities.3 The pathophysiology of
cortical myoclonus remains to be elucidated, but one hypothesis is
that it is a result of failed inhibition in neuronal circuits.3
Consistent with this theory, a 24–50% reduction in GABA-served.
Fig. 1. Electroencephalography (EEG) during myoclonic jerks showing spike-wave and polyspike-wave activity. This pattern disappeared temporarily after diazepam infusion
and permanently after withdrawal of meropenem.
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posthypoxic myoclonus and progressive myoclonic epilepsy.3 Not
surprisingly, GABAergic drugs such as benzodiazepines and
sodium valproate form the cornerstone of myoclonus treatment.3
Therefore, the characteristic EEG ﬁndings suppressed by a
GABAergic drug in our case were considered highly suggestive
of myoclonus of cortical origin.
As an adverse drug reaction, myoclonus is rare.4 One particulari-
ty in such cases is the temporal relationship between the beginning
of the symptoms and when the drug is started and between
remission of myoclonus and withdrawal of the offending drug.4Table 1
Laboratory ﬁndings, occurrence of myoclonus and use of meropenem.
Laboratory ﬁndings Day 1 Day 2 
Hemoglobin (106/mL) 12.4 11.6 
WBC (106/mL) 10.350 10.720 
Platelet count 409.000/mL 342.000/mL 
Urea 159 mg/dL 85 mg/dL 
Creatinine 5.9 mg/dL 3.2 mg/dL 
Potassium 5.1 mEq/L 4.3 mEq/L 
Sodium 121 mEq/L 127 mEq/L 
Myoclonus  + 
Meropenem 500 mg 10 pm 6 am
2 pm
WBC, white blood cells.Many drugs, including anti-infectious agents, are reported to
induce myoclonus.2,4 b-lactams are the most frequently implicat-
ed antibiotics in drug-induced seizures.1 and are reported to have
epileptogenic potential as a result of inhibition of the GABAergic
system and neurotoxicity, the b-lactam ring probably being an
important contributor to the epileptogenic properties.2 Accord-
ingly, seizures are a known adverse effect of carbapenem
antibiotics and are most commonly seen in patients receiving
imipenem, which has more proconvulsive properties than
meropenem2 (seizure rate 3–33% versus <1%, respectively).1
However, no consistent data about seizure semiology is available.Day 3 Day 4 Day 5
11.3 11.4 11.3
6.310 10.710 10.010
271.000/mL 343.000/mL 320.000/mL
85 mg/dL 75 mg/dL 91 mg/dL
2.6 mg/dL 2.5 mg/dL 2.8 mg/dL
3.4 mEq/L 5.2 mEq/L 3.0 mEq/L
129 Eq/L 123 mEq/L 130 mEq/L
+ +/ 
2 pm  
T. Spina Silva et al. / Seizure 23 (2014) 912–914914Although CNS impairment is a predisposing factor for
carbapenem-associated seizures and antiarrhythmic drugs such
as amiodarone, antidepressants and renal failure are associated
with myoclonus,3 the presence of the latter factors, while probably
contributing to the condition, was not sufﬁcient to explain the
myoclonus in this case as they did not change before the
myoclonus disappeared.
Reports of myoclonus following administration of meropenem
are scarce. Nevertheless, the epileptogenicity of this drug should
not be forgotten, especially for those patients with renal failure and
a complex clinical scenario.3
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